Polatuzumab
- Generic Name
- Polatuzumab
Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in?
The treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has evolved with the introduction of anti-CD19 CAR T-cell therapy and other novel agents. Despite these advancements, challenges such as patient eligibility, access to care, and treatment logistics persist. A phase III trial, ECHELON-3, evaluated the efficacy of Brentuximab vedotin (BV) combined with lenalidomide and rituximab (R) in patients with R/R DLBCL, showing improved overall survival compared to placebo plus Len + R. However, the study raises questions about the role of CD30 targeting in DLBCL treatment and the optimal sequencing of therapies.
Lisocabtagene Maraleucel Shows Promise in Relapsed/Refractory Lymphomas
• Lisocabtagene maraleucel (liso-cel) demonstrates efficacy and safety in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL), aligning with pivotal trial outcomes.
• The TRANSCEND FL trial indicates liso-cel achieved a significant overall response rate in relapsed/refractory marginal zone lymphoma (MZL), meeting the primary endpoint.
• Five-year data from TRANSCEND-NHL-001 underscore the curative potential of liso-cel in third-line LBCL, showing a 38% overall survival rate.
• Real-world data supports liso-cel's effectiveness across diverse LBCL patient subgroups, reinforcing its role as a standard-of-care treatment option.
Polatuzumab Offers New Hope for Diffuse Large B-Cell Lymphoma Treatment in India
• Polatuzumab, a first-in-class anti-CD79b antibody-drug conjugate, has been approved in India for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
• Clinical trial data indicates a 27% reduction in the risk of disease progression, relapse, or death compared to the standard R-CHOP chemotherapy regimen.
• Experts emphasize the importance of early and effective treatment with Polatuzumab to prevent relapse, particularly within the first two years post-treatment.
• The availability of Polatuzumab represents a significant advancement, offering improved outcomes for DLBCL patients in India.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath